Chemours (CC) reported Q3 EPS of $1.24, $0.17 better than the analyst estimate of $1.07. Revenue for the quarter came in at $1.78 billion versus the consensus estimate of $1.68 billion.
GUIDANCE:
As previously announced, Adjusted EBITDA for FY 2022 is expected to be between $1.40 billion and $1.45 billion. Free Cash Flow is expected to be greater than $575 million.
Mr. Newman concluded, "Looking ahead, we believe we have the best assets, team, and strategy to continue to deliver strong performance through the economic cycle and create value for our stakeholders, despite the macroeconomic uncertainty. We remain focused on our four key priorities to enhance shareholder value, and on delivering another solid year of financial results.”